Contract Development & Manufacturing Organisations (CDMOs) increasingly need to differentiate and establish their competitive advantage to effectively cater to the growing demand and to enhance their profitability. There is a greater demand for CDMOs offering broad-based best practice technologies, staff competencies and reliable delivery.
PharmaVentures is recognised as a leading transactions advisor and has advised on the strategic direction of over 40 facilities offering CRO/CDMO services and completed the sale of 14 operations globally.
In this white paper, we harness the knowledge from our extensive cross border transaction experience and industry research to look at the value drivers in the CDMO market that companies should keep in mind when they cultivate their strategies.
